Saint-Petersburg experience of allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and human immunodeficiency virus

Afanasyev, Boris; Popova, M.; Bondarenko, Sergey N.; Zyuzgin, Ilya; Babenko, Elena V.; Alyanskiy, Aleksander; Morsch, Susanne; Lunzen, Jan van; Zander, Axel R.; Zubarovskaya, Ludmila

doi:10.18620/1866-8836-2015-4-1-2-24-30

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Впервые алло-ТГСК пациенту с хроническим миелолейкозом и ВИЧ на фоне непрерывной АРВТ была выполнена в 1997 г. Первый опыт в последу-ющем позволил успешно применять этот метод для лечения пациентов с лейкозами и лимфомами на фоне ВИЧ-инфекции [14][15][16]. В группе пациен-тов, у которых по тем или иным причинам прием препаратов АРВТ был прекращен, наблюдался воз-врат активной инфекции ВИЧ и ухудшение общей выживаемости [16,17].…”

Section: вич и лимфомыunclassified

Gene-Cell Therapy of Hiv and Hematological Malignances Based on Hematopoietic Stem Cell Transplantation and Site-Specific Genome Editing

Popova¹,

Sergeev²,

Lepik³

et al. 2017

test

View full text Add to dashboard Cite

Section: вич и лимфомыunclassified

Gene-Cell Therapy of Hiv and Hematological Malignances Based on Hematopoietic Stem Cell Transplantation and Site-Specific Genome Editing

Popova¹,

Sergeev²,

Lepik³

et al. 2017

test

View full text Add to dashboard Cite

“…Allogeneic SCT in HIV patients has been performed from various stem cell sources including related and unrelated adult donors, cord blood, haploidentical donors, and combination treatment with cord blood and haploidentical donors, but it is still open whether this or the choice of the conditioning regimen has an effect on HIV latency [10,11]. A further point in discussion is the impact of different regimen of ART during transplantation and engraftment, whereas the addition of CCR5 inhibitors (like maraviroc) during the transplantation and engraftment period was without beneficial effect [12,13].…”

mentioning

confidence: 99%

HIV+ patients and HIV eradication – allogeneic transplantation

Hütter

2016

Expert Review of Hematology

View full text Add to dashboard Cite

Plasmablastic Lymphoma in HIV-Positive Patients: A Literature Review and Results of a Russian Multi-Center Retrospective Study

Popova

Tsygankov

Gudozhnikova

et al. 2022

Клиническая онкогематология

View full text Add to dashboard Cite

Background. Plasmablastic lymphoma (PBL) is a rare lympho-proliferative disease which is almost exclusively associated with immunodeficiency. Most ample experience of chemotherapy and hematopoietic stem cells transplantation (HSCT) in this lymphoma variant has been accumulated in HIV-positive patients. Aim. To describe the current approaches to PBL diagnosis and treatment in HIV-positive patients as well as to provide the results of the first multi-center retrospective study on PBL epidemiology and therapy efficacy in HIV-positive patients in the Russian Federation. Materials & Methods. The study included 26 HIV-positive patients with PBL who were treated and followed-up at 5 Russian centers during 2012-2019. The present study is a part of multi-center retrospective study on lymphoma epidemiology in HIV-positive patients in Russia. Results. PBL accounted for 9.5 % of all lymphomas in HIV-positive patients enrolled in multi-center retrospective study on lymphoma epidemiology in HIV-positive patients in Russia. Epidemiological characteristics of these patients corresponded to those described in previously published literature: the disease being diagnosed mainly at late stages (88 %), oral and nasal mucosa lesions with a common involvement of facial bones (65 %), and lack of optimal HIV-infection control (66.7 %). Most commonly, the patients received EPOCH-like treatment as first-line therapy (50 %). However, the efficacy of primary therapy appeared to be low. Overall survival (OS) and progression-free survival (PFS) during a year after first-line therapy onset was 57 % and 46 %, respectively. Bortezomib included in first-line therapy was associated with a trend to a more favorable prognosis. Half of patients showed a lymphoma relapse or progression after first-line therapy. Most used second-line regimen was DHAP. Overall response to second-line therapy was 38.5 %. After second-line therapy onset, 1-year OS and PFS were 26 % and 15 %, respectively. Conclusion. HIV-positive patients with PBL have poor prognosis. Efforts to improve the prognosis for HIV-positive patients with PBL should be aimed at increasing the efficacy of first-line therapy and should involve the use of intensive chemotherapy regimens with bortezomib. The role of auto-and allo-HSCTs in the treatment of PBL has not been clearly determined, however, PBL patients, despite their HIV-infec-tion, should be regarded as auto-HSCT-eligible in the first remission and allo-HSCT-eligible in case of relapse. Further prospective multi-center studies are needed to optimize the treatment of HIV-positive patients with PBL.

show abstract

Saint-Petersburg experience of allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and human immunodeficiency virus

Cited by 3 publications

References 36 publications

Gene-Cell Therapy of Hiv and Hematological Malignances Based on Hematopoietic Stem Cell Transplantation and Site-Specific Genome Editing

Gene-Cell Therapy of Hiv and Hematological Malignances Based on Hematopoietic Stem Cell Transplantation and Site-Specific Genome Editing

HIV+ patients and HIV eradication – allogeneic transplantation

Plasmablastic Lymphoma in HIV-Positive Patients: A Literature Review and Results of a Russian Multi-Center Retrospective Study

Contact Info

Product

Resources

About